[go: up one dir, main page]

SV2009003295A - Derivados de aril sulfamida y metodos para su uso - Google Patents

Derivados de aril sulfamida y metodos para su uso

Info

Publication number
SV2009003295A
SV2009003295A SV2009003295A SV2009003295A SV2009003295A SV 2009003295 A SV2009003295 A SV 2009003295A SV 2009003295 A SV2009003295 A SV 2009003295A SV 2009003295 A SV2009003295 A SV 2009003295A SV 2009003295 A SV2009003295 A SV 2009003295A
Authority
SV
El Salvador
Prior art keywords
disorders
aril
methods
derivatives
sulfamide derivatives
Prior art date
Application number
SV2009003295A
Other languages
English (en)
Inventor
Comas Casey Cameron Mc
Stephen Todd Cohn
Joel Adam Goldberg
Caflain Younghee Kim
Charles William Mann
David John O'neill
Joseph P Sabatucci
An Thien Vu
Richard Page Woodworth Jr
Puwen Zhang
Eugene Anthony Terefenko
Matthew L Crawley
Andrew Fensome
Douglas John Jenkins
Paige Erin Mahaney
Eugene John Trybulski
Michael Anthony Marella
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SV2009003295A publication Critical patent/SV2009003295A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCIÓN SE DIRIGE A DERIVADOS DE ARIL SULFAMIDA DE LA FORMULA I: (VER FORMULA); O UNA SAL FARMACÉUTICAMENTE ACEPTABLE, ESTEREOISÓMERO O TAUTÓMERO DE ESTOS, QUE SON INHIBIDORES DE RECAPTACIÓN DE MONOAMINA, COMPOSICIONES QUE CONTIENEN ESTOS DERIVADOS, Y MÉTODOS PARA SU USO PARA LA PREVENCIÓN Y TRATAMIENTO DE AFECCIONES, QUE INCLUYEN, INTER ALIA, SÍNTOMAS VASOMOTRICES, DISFUNCIÓN SEXUAL, TRASTORNOS GASTROINTESTINALES Y TRASTORNO GENITOURINARIO, TRASTORNOS DEPRESIVOS, TRASTORNOS DE COMPORTAMIENTO ENDÓGENO, TRASTORNOS COGNITIVOS, NEUROPATÍA DIABÉTICA, DOLOR, Y OTROS ENFERMEDADES Y TRASTORNOS
SV2009003295A 2006-12-12 2009-06-11 Derivados de aril sulfamida y metodos para su uso SV2009003295A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86964406P 2006-12-12 2006-12-12

Publications (1)

Publication Number Publication Date
SV2009003295A true SV2009003295A (es) 2009-10-29

Family

ID=39273293

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003295A SV2009003295A (es) 2006-12-12 2009-06-11 Derivados de aril sulfamida y metodos para su uso

Country Status (20)

Country Link
US (4) US20080161366A1 (es)
EP (1) EP2061776A1 (es)
JP (1) JP2010512401A (es)
KR (1) KR20090087506A (es)
CN (1) CN101600701A (es)
AR (1) AR064318A1 (es)
AU (1) AU2007333593A1 (es)
BR (1) BRPI0720289A2 (es)
CA (1) CA2671844A1 (es)
CL (1) CL2007003590A1 (es)
CR (1) CR10866A (es)
EC (1) ECSP099411A (es)
MX (1) MX2009006359A (es)
NO (1) NO20092092L (es)
PE (1) PE20081395A1 (es)
RU (1) RU2009121017A (es)
SV (1) SV2009003295A (es)
TW (1) TW200843753A (es)
WO (1) WO2008073459A1 (es)
ZA (1) ZA200904109B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076502A1 (en) * 2007-12-12 2009-06-18 Wyeth Methods for the preparation of hydroxy-substituted aryl sulfamide compounds
GB0813694D0 (en) * 2008-07-25 2008-09-03 Glaxo Group Ltd Compounds
US9108937B2 (en) * 2010-03-04 2015-08-18 Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2
CN102838567B (zh) * 2011-06-23 2014-12-31 深圳市湘雅生物医药研究院 一种苯磺酰或苯甲酰哌嗪类化合物及其制备方法和用途
EP2776387B1 (en) * 2011-11-07 2017-02-01 Emory University Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
US9867813B2 (en) * 2015-11-17 2018-01-16 Thomas Daly Aminopyridine based buffers with wide buffering ranges, antibiotics and myelin disease therapy
CN107337616A (zh) * 2017-07-13 2017-11-10 上海昕盛医药科技有限公司 一种盐酸班布特罗杂质f的合成方法
CN107445845A (zh) * 2017-08-24 2017-12-08 重庆沃肯精细化工有限公司 一种合成氯法齐明关键中间体n‑(4‑氯苯基)‑1，2‑苯二胺的方法
WO2019243523A1 (en) * 2018-06-21 2019-12-26 Cellestia Biotech Ag Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts
WO2021138540A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer
CN116003261A (zh) * 2022-12-19 2023-04-25 江苏康恒化工有限公司 新型聚氨酯扩链剂2-氨基-2’-氯二苯胺的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3177221A (en) * 1963-02-05 1965-04-06 Mcneilab Inc 2, 1, 3-benzothiadiazoline-2, 2-dioxides
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
ZA966885B (en) * 1995-08-22 1998-02-16 Du Pont Merck Pharma Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors.
GB9825413D0 (en) * 1998-11-19 1999-01-13 Lilly Co Eli Pharmaceutical compounds
HU230538B1 (hu) * 2000-08-14 2016-11-28 Ortho Mcneil Pharmaceutical, Inc. Szubsztituált pirazolok és ezeket tartalmazó gyógyszerkészítmények
KR100729242B1 (ko) * 2001-04-18 2007-06-15 유로-셀티크 소시에떼 아노뉨 노시셉틴 유사체
MXPA04006344A (es) * 2001-12-28 2005-03-31 Takeda Pharmaceutical Preventivos/remedios para la perturbacion de miccion.
WO2006114706A1 (en) * 2005-04-26 2006-11-02 Pfizer Limited Triazole derivatives as vasopressin antagonists
WO2007041258A1 (en) * 2005-09-29 2007-04-12 Wyeth Benzothiadiazolyphenylalkylamine derivatives for use in the treatment of conditions ameliorated by monoamine reuptake

Also Published As

Publication number Publication date
NO20092092L (no) 2009-08-19
US20100029641A1 (en) 2010-02-04
MX2009006359A (es) 2009-06-26
EP2061776A1 (en) 2009-05-27
CL2007003590A1 (es) 2008-02-29
US20080194654A1 (en) 2008-08-14
ECSP099411A (es) 2009-07-31
JP2010512401A (ja) 2010-04-22
BRPI0720289A2 (pt) 2014-02-04
ZA200904109B (en) 2010-04-28
WO2008073459A1 (en) 2008-06-19
CN101600701A (zh) 2009-12-09
CR10866A (es) 2009-07-14
PE20081395A1 (es) 2008-09-17
AU2007333593A1 (en) 2008-06-19
CA2671844A1 (en) 2008-06-19
RU2009121017A (ru) 2011-01-20
US7601722B2 (en) 2009-10-13
US20080161366A1 (en) 2008-07-03
AR064318A1 (es) 2009-03-25
US20080167303A1 (en) 2008-07-10
TW200843753A (en) 2008-11-16
KR20090087506A (ko) 2009-08-17

Similar Documents

Publication Publication Date Title
SV2009003295A (es) Derivados de aril sulfamida y metodos para su uso
ECSP10010035A (es) Amidas heterocíclicas y sus métodos de uso
NO20061253L (no) Acetylenderivater som inhibitorer av histon deacetylase
BRPI0409227C1 (pt) composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
EA200970156A1 (ru) Пиридизиноновые производные
NO20082346L (no) Hydrazonderivater og anvendelser derav
ECSP099706A (es) Nuevos derivados de n-(8-heteroariltetrahidronaftalen-2yl) y n-(5-heteroarilcroman-3-il) carboxamida para el tratamiento del dolor
EA201070535A1 (ru) Новые агонисты глюкокортикоидных рецепторов
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
WO2007095050A3 (en) N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
CR10479A (es) Modulares bencimidazolicos de vr1
ECSP088457A (es) Compuestos de benzamida útiles como inhibidores de la histona deacetilasa
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
MA32240B1 (fr) Inhibiteurs de désacétylases b à base d'hydroxamate
BRPI0809542A8 (pt) Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos
CU20210016A7 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
ATE474574T1 (de) Imidazoazephinonverbindungen
AR052413A1 (es) Nuevos derivados de piridotienopiriidina